Transcranial direct current stimulation (tDCS) as a therapeutic intervention for post-acute sequelae of SARS-CoV-2 (PASC)

Czech Health Research Council0 个研究点目标入组 33 人开始时间: 2022年5月6日最近更新: 2024年3月11日

适应症

试验速览

2024 Results article in https://doi.org/10.1038/s41598-024-52763-4 (added 28/02/2024)

•Current participant inclusion criteria as of 10/11/2023:
•1. Male and female outpatients aged 18-75 years with a history of COVID-19 and monitored by an outpatient physician for mental disorders (anxiety, mood disorders, sleep) within the PASC
•2. PCR RNA SARS-CoV-2 negativity at screening/study entry
•3. Duration of symptoms >1 and =24 months after detection of COVID-19
•4. The mental ability to understand and sign the Informed Consent Form
•5. Presence of neuropsychiatric PASC symptoms as determined by A-PASC with a minimum overall score =25 (cognitive score, emotional and functional impairment)
•6. FIS questionnaire score =40
•7. Psychopharmacological medication (if used) at a stable dose =4 weeks.
•Previous participant inclusion criteria:
•1. Male and female outpatients aged 18-75 years with a history of COVID-19 and monitored by an outpatient physician for mental disorders (anxiety, mood disorders, sleep) within the PASC
•2. PCR RNA SARS-CoV-2 negativity at screening/study entry
•3. Duration of symptoms >1 and =18 months after detection of COVID-19
•4. The mental ability to understand and sign the Informed Consent Form
•5. Presence of neuropsychiatric PASC symptoms as determined by A-PASC with a minimum overall score =25 (cognitive score, emotional and functional impairment)
•6. FIS questionnaire score =40
•7. Psychopharmacological medication (if used) at a stable dose =4 weeks.

•1. Contraindications of tDCS (skin disease, superficial injury, and fracture or infraction of skull in the stimulation area, epilepsy, metallic plates in the head)
•2. History of any other DSM-IV axis I diagnosis prior to COVID-19, except for:
•2.1. Depressive disorders, anxiety disorders, and sleep disorders that may be present in the history, but with at least 6 months of documented remission of symptoms
•2.2. Disorders associated with the use of addictive substances at least 6 months before entering the study
•3. Pregnancy or breastfeeding
•4. Patients with severe and/or unstable somatic disorders (cardiovascular disease, neoplasms, endocrinology disorders, etc)
•5. Patients suffering from a serious neurological disorder (eg epilepsy, head injury with loss of consciousness)

发起方

Czech Health Research Council